Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MDM2 amp TP53 wild-type |
| Therapy | BI 907828 + Ezabenlimab |
| Indication/Tumor Type | gallbladder adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MDM2 amp TP53 wild-type | gallbladder adenocarcinoma | predicted - sensitive | BI 907828 + Ezabenlimab | Case Reports/Case Series | Actionable | In a Phase Ia/Ib trial, treatment with the combination of BI 907828 and Ezabenlimab (BI 754091) resulted in a partial response with a progression-free survival of 7.9 months in a patient with MDM2-amplified (CN=14), TP53 wild-type metastatic gallbladder adenocarcinoma (PMID: 38567193; NCT03964233). | 38567193 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38567193) | Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series. | Full reference... |